Golden Helix and Fluxion Biosciences Join in a Global, Value-Added Reseller Agreement

Bozeman, MT (February 16, 2015) — Golden Helix, Inc. and Fluxion Biosciences, Inc. announced their collaboration in a value-added reseller relationship today, focused on the VarSeq software application for next-generation sequencing (NGS) analysis.

"Providing our global client base with a method to study tumor DNA in the circulation is a capability we are proud to offer", said Jeff Jensen, CEO of Fluxion. "Offering the VarSeq software to our customers is a critical step toward our goal of a complete sample-to-answer workflow for NGS profiling of cancer from a blood sample."

Fluxion is a leader in the molecular profiling of tumor cells using a routine blood draw, having commercialized the IsoFlux System for routine sequencing of circulating tumor cells (CTCs) using targeted cancer panels. This partnership will leverage Golden Helix's VarSeq software in order to provide IsoFlux customers with clinical analytic capabilities.

"The analysis of blood samples for cancer diagnosis is a key area to advancing precision medicine. Golden Helix is excited to support Fluxion Biosciences in this area," said Andreas Scherer, CEO of Golden Helix.

VarSeq software streamlines the process of annotating and filtering variants obtained from NGS pipelines, allowing both research scientists and clinicians to find variants of interest in a very efficient and straightforward manner. VarSeq simplifies the user interface and provides a scalable architecture featuring repeatable workflows, note taking, reporting, and filter parameter prototyping.

 

About Golden Helix
Golden Helix has been delivering industry leading bioinformatics solutions for the advancement of life science research and translational medicine for over 16 years. Our innovative technologies and analytic services empower scientists and healthcare professionals at all levels to derive meaning from the rapidly increasing volumes of genomic data produced from micro-arrays and DNA sequencing. With our solutions, hundreds of the world's top pharmaceutical, biotech, and academic research organizations are able to harness the full potential of genomics to identify the cause of disease, improve the efficacy and safety of drugs, develop genomic diagnostics, and advance the quest for personalized medicine. Golden Helix products and services have been cited in over 800 peer-reviewed publications.

 

About Fluxion Biosciences
Fluxion Biosciences brings the power of cellular analysis to the benchtop with advanced tools to automate complex assays. The company's IsoFlux System enables translational oncology research using a non-invasive Blood Biopsy™. This platform utilizes high-sensitivity circulating tumor cell (CTC) collection to facilitate broad-based genomic analysis using tools such as Next Generation Sequencing (NGS). This approach provides a more comprehensive look at the disease status, as compared to alternative approaches that only look at limited panels of known mutations. Fluxion's other products, the BioFlux System and IonFlux System, have helped hundreds of research institutions and pharmaceutical companies around the world advance their cellular research and drug discovery..

 

###

Cheryl Rogers
Director of Marketing
Golden Helix, Inc. 
406-999-0176
rogers@goldenhelix.com
--
Jeff Jensen
CEO
Fluxion Biosciences, Inc.
1 (650) 241-4747
jeff.jensen@fluxionbio.com